Osteoporosis: What You Had, What You Lost, and What You Gain


Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of the Phase 3 Open-Label Structure Study
B Langdahl, C Libanati, D B Crittenden, M A Bolognese, J P Brown, N S Daizadeh, E Dokoupilova, K Engelke, J S Finkelstein, H K Genant, S Goemaere, L Hyldstrup, E Jodar-Gimeno, T M Keaveny, David L Kendler, P Lakatos, J Maddox, J Malouf, F Massari, J F Molina, M R Ulla and A Grauer


Abaloparatide Significantly Reduces Vertebral and Nonvertebral Fractures and Increases BMD Regardless of Baseline Risk
Felicia Cosman, Gary Hattersley, Paul D Miller, Ming-yi Hu, Luis Augusto Russo, Bente Juel Riis, Gregory C Williams and Lorraine A Fitzpatrick


Anti-Mullerian Hormone and Prediction of Trans-Menopausal Bone Loss
Arun S Karlamangla, Albert Shieh, Sherri-Ann M Burnett-Bowie, Elaine W. Yu, Gail A Greendale, Patrick M. Sluss, Deborah Martin and Joel S Finkelstein


Low Plasma Leucine-Rich Repeat-Containing 17 (LRRc17) Level Is an Independent and Additive Risk Factor for Prevalent Vertebral Fractures in Postmenopausal Women
Namki Hong, Beom-Jun Kim, Chong Hwa Kim, Ki-Hyun Baek, Yong-Ki Min, Deog-Yoon Kim, Seung Hun Lee, Jung-Min Koh, Moo-Il Kang and Yumie Rhee


Use of Stimulant Medications and Bone Mass in Children and Adolescents: An Nhanes Study
Alexis Jamie Feuer, Ashley Thai, Ryan T Demmer and Maria G Vogiatzi


Delay in Oestrogen Commencement Is Associated with Lower Spine and Hip Bone Mineral Density in Turner Syndrome
Hanh Nguyen, Phillip Wong, Boyd J Strauss, Peter R Ebeling, Frances Milat and Amanda Vincent